Business
Elanco Secures Approval of Zenrelia™ (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itchy Dogs
Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has received approval by the European Commission.
About this update from Elanco Animal Health Incorporated
[{"type":"list","items":[{"val":[{"type":"text","content":"The European Commission's Approval of Zenrelia reinforces safety and efficacy and further expands opportunities to treat itchy dogs around the world","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"Launch to begin immediately with product in market before the end of Q3 2025","length":76,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":228,"olType":false},{"type":"text","content":"GREENFIELD, Ind., July 24, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has received approval by the European Commission.","length":190,"tagName":"p"},{"type":"image","alt":"Elanco logo (PRNewsfoto/Elanco Animal Health)","displaySize":"","headline":null,"caption":"Elanco logo (PRNewsfoto/Elanco Animal Health)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":267,"url":"https://media.zenfs.com/en/prnewswire.com/3e0d7ba65d33b7150e97f71c77abc8af"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LM_acgCT_vHsVMsjwpFxgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/3e0d7ba65d33b7150e97f71c77abc8af","width":400,"height":267}},"href":"https://mma.prnewswire.com/media/2309278/Elanco_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"This approval by the EU reinforces Zenrelia's status as a highly effective, convenient, and safe once-daily oral JAK inhibitor. Zenrelia's approval represents a significant milestone in the EU canine dermatology market, offering a once-daily tablet solution for control pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.","length":400,"tagName":"p"},{"type":"text","content":""Our EU approval for Zenrelia is a pivotal achievement, making it our most rapidly expanding product and solidifying our position as a leader in pet health innovation," stated Dr. Ellen de Brabander, Executive Vice President of Innovation and Regulatory Affairs at Elanco. "We've seen remarkable results from our rigorous head-to-head study against the market leader and in real-world settings where Zenrelia is already approved and being used. We're excited to provide veterinarians across the EU with this impactful solution, of...